HemaSure seeks approval of blood filter:
This article was originally published in Clinica
HemaSure has filed a 510(k) application with the FDA to market its r/LS red blood cell filter in the US. The filter removes white blood cells (leukocytes) from red blood cell concentrates and in doing so reduces the risk of transmission of viruses on the back of leukocytes such as Hepatitis B and C and Epstein Barr virus. It is designed to be used for high volumes of blood where there is a need for cost effectiveness. The Marlborough, Massachusetts-based company has already CE-marked the filter.
You may also be interested in...
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.
While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.